Age: 55.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Interchange of vaccine products, SARS-CoV-2 test, Vaccination failure
Clinical narrative: vaccination failure; cold like symptoms/stuffy nose/COVID-19; Interchange of vaccine products; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION FAILURE (vaccination failure), COVID-19 (cold like symptoms/stuffy nose/COVID-19) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for Prophylactic vaccination.    Co-suspect product included non-company product COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for Prophylactic vaccination.    Concurrent medical conditions included Itchy eyes (The patient had unspecified allergies (had allergies, Itchy eyes runs and runny nose from allergies,  did not know what she was allergic to and took a medication in evenings for it.) and Runny nose.   On 08-Mar-2021, the patient started COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) (unknown route) 1. On 23-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Oct-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). On 12-Jan-2022, the patient experienced VACCINATION FAILURE (vaccination failure) and COVID-19 (cold like symptoms/stuffy nose/COVID-19). On 23-Oct-2021, INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) had resolved. At the time of the report, VACCINATION FAILURE (vaccination failure) outcome was unknown and COVID-19 (cold like symptoms/stuffy nose/COVID-19) had not resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 12-Jan-2022, SARS-CoV-2 test: positive (Positive) Positive.         No concomitant medication was reported. The patient had received Moderna COVID-19 Vaccine booster dose. The covid-19 rapid POC test was done. No treatment information was provided.  Company Comment: This spontaneous case concerns a 55 year old female  initially vaccinated with Covid 19 vaccine Janssen , who experienced , Non-serious , unexpected, AESI   event of Covid 19 and non-serious , unexpected event of Vaccination failure which occurred  2 months 21 days post vaccination with the booster dose of mRNA-1273 vaccine ( Moderna Covid 19 vaccine ) . A non-serious , unexpected event of Interchange of vaccine products was also coded for this case. The re-challenge for this case is not applicable . The history of vaccination with the Covid 19 vaccine Janssen is considered as a confounder for this case. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.; Sender's Comments: This spontaneous case concerns a 55 year old female  initially vaccinated with Covid 19 vaccine Janssen , who experienced , Non-serious , unexpected, AESI   event of Covid 19 and non-serious , unexpected event of Vaccination failure which occurred  2 months 21 days post vaccination with the booster dose of mRNA-1273 vaccine ( Moderna Covid 19 vaccine ) . A non-serious , unexpected event of Interchange of vaccine products was also coded for this case. The re-challenge for this case is not applicable . The history of vaccination with the Covid 19 vaccine Janssen is considered as a confounder for this case. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.